Clinical Trials Directory

Trials / Completed

CompletedNCT04582097

Ramipril in Pediatric Patients on Hemodialysis

Impact of Angiotensin-converting Enzyme Inhibitor on Pediatric Hemodialysis Patients

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
135 (actual)
Sponsor
Ain Shams University · Academic / Other
Sex
All
Age
8 Years – 16 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to evaluate the effect of Ramipril in pediatric patients on regular hemodilaysis

Detailed description

Evaluate the effect of Ramipril on blood pressure, heart rate, Endothelial dysfunction and inflammatory markers in pediatric patients on regular hemodilaysis and the correlation of response with ACE I/D polymorphisms.

Conditions

Interventions

TypeNameDescription
DRUGRamiprilangiotensin-converting enzyme inhibitor
DRUGplacebosame odor, color and size as the drug but without the active ingredient

Timeline

Start date
2018-12-01
Primary completion
2019-03-01
Completion
2020-02-28
First posted
2020-10-09
Last updated
2020-10-14

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04582097. Inclusion in this directory is not an endorsement.

Ramipril in Pediatric Patients on Hemodialysis (NCT04582097) · Clinical Trials Directory